Considering that Momenta received the best possible outcome from the FDA something doesn't make sense.
You got that right.
I have been buying market anomalies for thirty years. MNTA looks like another one - a significant under-pricing of the stock.
Yet the consistently rising short interest suggests the stock goes lower.
Who is right? The longs? Or the shorts and insider sellers?
As you say time will tell.
But to conclude that mL is not a very profitable drug with high sales is error unless Wheeler is intentionally misleading the stockholders. That possibility is close to inconceivable given that the truth will be known so soon that Wheeler would have to be an idiot to do that.
Jbog - Is that what you thought when Imclone tanked?
I sat through that and I will sit through this. Even if you think Teva is capable of approval, you have to know MNTA is capable of duplicating many more drugs with very large markets. Time is on our side.
I appreciate your thoughts and it's nice to hear a voice from the other side.
Market Data 
Markets 
AI
